Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGB-500 1% Tofacitinib Ointment vs. Active Comparator for Atopic Dermatitis
NCT06923228Phase 2Completed
- Sponsor
- CAGE Bio
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of CGB-500 in atopic dermatitis (AD) (2 arms), sponsored by CAGE Bio. Primary endpoints: Effectiveness of CGB-500 at 4 weeks and Safety and Tolerability at 4 weeks. Started Apr 2025; status: completed.
02
Drugs
CGB-500
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06923228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923228.